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 Abstract 
For estimation of Valsartan in pharmaceutical dosage form, a simple, accurate and precise area under curve 
spectrophotometric method was developed. The area under two points on the mixture spectra is directly proportional to the 
concentration of the component of interest is the AUC curve. The area selected for estimation of Valsartan was between 
238.20 to 254.40 nm. The method represented regression coefficient (r2 = 0.996) at concentration rang 2-10 μg/ml. 
Estimation of the drugs was found up to 100 % representing the accuracy of the method. The recovery of the Valsartan was 
found up to 100 %. Validation of the proposed method was carried out for its accuracy, precision and specificity according 
to ICH Q2 (R1) guidelines. The developed methods can be successfully applied in routine work for the estimation of 
Valsartan in its pharmaceutical dosage form. 
Keywords: Valsartan; UV; AUC. 
1. Introduction  
Valsartan1 is a non-peptide, orally active and 
specific angiotensin II receptor blocker acting on the AT1 
receptor subtype. Valsartan in chemically described as N-
(1-oxopentyl)-N-[2'(1H-tetrazol -5 yl)[ 1,1'biphenyl]4-yl 
methyl]L-valine. Valsartan is used for treatment of 
hypertension, can be used alone or in combination with 
other antihypertensive drugs. Only LC-MS in human 
plasma, Colorimetric estimation, RP-HPLC and degration 
studies by isocratic HPLC has been reported so far. The aim 
of this work is to develop simple, accurate, precise 
spectrophotometric methods for the routine determination 
of valsartan in bulk and tablet dosage form.[1-8,11]  
 
Figure 1: Chemical structure of Valsartan 
2. Materials and methods 
2.1 Chemicals 
Valsartan was supplied by Chempure 
Pharmaceuticals Ltd., Mumbai, India. Tablet of Valsartan 
10 mg (DIOVAN 40 mg) was procured from local 
pharmacy. 0.1N Sodium hydroxide was obtained from S.D. 
Fine Chemicals, Mumbai, India. All chemicals and reagents 
were of analytical reagent (AR) grade. 
2.2 Instrumentation 
A Shimadzu (Kyoto, Japan) model UV-1800 
double beam UV-Visible spectrophotometer attached with 
computer operated software UV probe 2.0 with spectral 
width of 2 nm, wavelength accuracy of 0.5 nm and pair of 1 
cm matched quartz cells was used to measure absorbance of 
the resulting solutions. Analytical balance, Mettler Toledo 
(Model JL1503-C). 
2.3 Preparation of Standard and Sample Stock Solution 
Transfer accurately weighed quantity of Valsartan 
(10 mg) to a separate 100 ml volumetric flask, dissolved 
and diluted up to the mark with 0.1N Sodium hydroxide to 
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get standard solution having concentration 100 μg/ml of 
Valsartan. Successive dilutions were carried out to get 10 
μg/ml of Valsartan which was scanned in the UV-region i.e. 
400 to 200 nm. In UV– Spectrophotometric method, two 
wavelengths 238.20 nm and 254.40 nm were selected for 
estimation of area under curve (AUC) of Valsartan. For 
Sample solution, Valsartan tablet was taken, 10 mg was 
transferred into 10 ml volumetric flask and make up the 
volume with distilled water. 1 ml from above solution was 
taken into 10 ml volumetric flask and make up volume with 
distilled water to get a final concentration of 100 μg/ml. 
2.4 Area under Curve: 
The AUC (area under curve) method was 
applicable where there is no sharp peak or when broad 
spectra are obtained. It involves the calculation of 
integrated value of absorbance with respect to the 
wavelength between the two selected wavelengths λ1 and 
λ2. Area calculation processing item calculates the area 
bound by the curve and the horizontal axis. The horizontal 
axis is selected by entering the wavelength range over 
which area has to be calculated. This wavelength range is 
selected on the basis of repeated observation so as to get the 
linearity between area under curve and concentration. The 
above mentioned spectrums were used to calculate AUC. 
Thus, the calibration curve can be constructed by plotting 
concentration versus AUC.[9] 
2.5 Method Validation: 
The method was validated as per the ICH 
guidelines. 
2.5.1 Linearity 
Standard solution of Valsartan (1.25, 2.5, 3.75, 5 
and 6.25 ml) was pipette out in to a separate series of 25 ml 
volumetric flask. The volume was adjusted to the mark with 
distilled water and mixed. The area under curve for 
solutions was measured between 238.20 to 254.40 nm 
against distilled water as blank. From using this area, the 
‘X’ value of the drug was determined at the selected AUC 
range.[10]
 
2.5.2 Precision 
Precision of the method was verified by 
repeatability and intermediate precision studies. 
Repeatability studies were performed by analyses solution 
(5-25 μg/ml) on the same day. The %RSD of six 
determinations was calculated. Intermediate precision of the 
method was checked by repeating studies on two different 
days. The %RSD of determinations was calculated.[10]
 
 
Figure 2: Area between 238.20-254.40 nm selected for 
valsartan tablet formulation (10 μg/ml) 
 
Table 1: Calibration Curve Data of Valsartan 
Conc.(ppm) AUC 
2 0.090 
4 0.152 
6 0.227 
8 0.304 
10 0.349 
12 0.433 
 
 
Figure 3: calibration curve of Valsartan 
2.5.3 Sensitivity 
The sensitivity of the method was determined in 
terms of limit of detection (LOD) and limit of quantitation 
(LOQ). The LOD and LOQ were calculated by using the 
formula, LOD = 3.3 × σ/S and LOQ = 10 × σ/S, 
Where, σ is standard deviation of regression line 
and S is slope of corresponding regression line.[10]
 
2.5.4 Recovery 
To study the accuracy of the proposed methods 
and to check the interference from excipients used in the 
dosage forms, recovery experiments were carried out by the 
standard addition.[10]
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Table 2: Regression Analysis Data for Valsartan by the 
Area under Curve 
Method Parameter AUC 
Wavelength range 238.20-254.40 nm 
Concentration range(μg/ml) 2-12 
Slope (m) 0.034 
Intercept (c) 0.020 
Correlation coefficient (r2) 0.996 
 
Table 3: Results of Intra and Inter Day Precision 
Parameter ±SD* %RSD* 
Interday 0.05 1.84 
Intraday 0.01 0.73 
*n=6 
Table 4: Data of Recovery Studies 
Level of Mean 
Recovery (%) 
% 
Mean 
Recovery 
SD* 
% 
RSD 
80% 99.65 0.5760 0.5802 
100% 99.97 0.5482 0.5497 
120% 99.75 0.7019 0.7068 
*n = 3 
Table 5: Assay Results for the Estimation of Valsartan 
in Pharmaceutical Formulation 
Parameter 
Labeled 
Claim 
(mg/tab) 
Amount 
Found 
(mg/tab) 
% 
Labeled 
Claim 
AUC 40 39.999 99.97% 
 
Table 6: Summary Data of Validation Parameters 
Sr. No. Parameter AUC Method 
1 Linearity range 2-12 
2 Regression equation Y=0.034x+0.020 
3 Correlation co-efficient R2=0.996 
4 LOD(μg /ml) 0.14 
5 LOQ (μg /ml) 0.448 
6 Precision  
 Intra day 0.73 
 Inter day 1.84 
7 % recovery 0.5760-0.7068 
 
2.5.5 Assay Procedure 
Twenty tablets (Valsartan) containing 10 mg of 
Valsartan weighed, average weight calculated and triturated 
to fine powder and then weight equivalent 10 mg of 
Valsartan transferred into 10 ml volumetric flask and 
dissolved in water and diluted up to the mark with water to 
get a solution containing of 1000 μg/ml from the 2.5 ml was 
transferred to 25 ml volumetric flask and diluted up to the 
mark with water to get Valsartan solution containing 100 
μg/ml of Valsartan. From above solution 2.5 ml was 
transferred to 25 ml volumetric flask and diluted up to the 
mark with water and to produce 10 μg/ml solution of 
Valsartan. 10 μg/ml of Valsartan which was scanned in the 
UV-region i.e. 400 to 200 nm. 
3. Results and discussion 
The area under the curve spectra for Valsartan was 
recorded at the wavelength of 238.20-254.40 nm. 
3.1 Linearity and Range 
Under the experimental conditions described, the 
graph obtained for area under the curve spectra showed 
linear relationship (Figure 3). Regression analysis was 
made for the slope, intercept and correlation-coefficient 
values. The regression equations of calibration curves were 
y = 0.034x-+0.020 (r2 = 0.996) at 238.20-254.40 nm for 
area under the curve spectrophotometry. The range was 
found to be 2-12 μg/ml for area under the curve 
spectrophotometric method (Table 1). 
3.2 Precision 
To determine the precision of the method, an 
Valsartan solution at a concentration 10 μg/ml was 
analyzed each six times for area under the curve 
spectrophotometric method. Solutions for the standard 
Curves were prepared fresh everyday (Table 3). 
3.3 Sensitivity 
The limit of detection (LOD) and limit of 
quantification (LOQ) were calculated by using the 
equations LOD = 3 x σ / S and LOQ = 10 x σ /S, where σ is 
the standard deviation of intercept, S is the slope. The LOD 
and LOQ were found to be 0.14 μg/ml and 0.448 μg/ml 
respectively for area under the curve method. 
3.4 Recovery 
To study the accuracy of the proposed methods 
and to check the interference from excipients used in the 
dosage forms, recovery experiments were carried out by 
thestandard addition method. This study was performed by 
addition of known amounts of Valsartan to reanalyzed 
solutions of commercial dosage form (Table 4). 
3.5 Analysis of Marketed Formulation 
There was no interference from the excipients. The 
drug content was found to be 99.97 % for area under the 
curve spectrophotometric method. It may therefore be 
inferred that degradation of Valsartan had not occurred in 
the marketed formulations that were analyzed by this 
method. The low % R.S.D. value indicated the suitability of 
this method for routine analysis of Valsartan (Table 5). 
 
4. Conclusion 
No any spectrophotometric methods have been 
described for AUC estimation of Valsartan. Therefore, 
simple, fast and reliable area under curve 
spectrophotometric method was developed for the routine 
analysis of Valsartan. The developed method can be 
concluded as accurate, sensitive and precise and can be 
easily applied to the pharmaceutical formulation. 
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